Elanco Animal Health Incorporated (ELAN) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $8.88B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-219.00M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $8.86B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-233.00M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $8.87B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-141.00M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $8.85B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-199.00M.
Elanco Animal Health Incorporated Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $0.00 | $8.88B | $-219.00M | $-2.07B | $6.59B | 3 month · $20.00M | (m) |
| 2026-03-31 | $0.00 | $0.00 | $8.86B | $-233.00M | $-2.12B | $6.50B | 3 month · $-12.00M | (m) |
| 2025-12-31 | $0.00 | $0.00 | $8.87B | $-141.00M | $-2.18B | $6.55B | 12 month · $53.00M | (m) |
| 2025-09-30 | (m) | $0.00 | $8.85B | $-199.00M | $-1.91B | $6.75B | 3 month · $15.00M | (m) |
| 2025-06-30 | (m) | $0.00 | $8.84B | $-192.00M | $-1.87B | $6.78B | 3 month · $20.00M | (m) |
| 2025-03-31 | (m) | $0.00 | $8.82B | $-583.00M | $-1.88B | $6.35B | 3 month · $2.00M | (m) |
| 2024-12-31 | $0.00 | $0.00 | $8.82B | $-771.00M | $-1.95B | $6.10B | 12 month · $40.00M | (m) |
| 2024-09-30 | (m) | $0.00 | $8.80B | $-339.00M | $-1.94B | $6.52B | 3 month · $14.00M | (m) |
| 2024-06-30 | (m) | $0.00 | $8.79B | $-542.00M | $-2.31B | $5.94B | 3 month · $13.00M | (m) |
| 2024-03-31 | (m) | $0.00 | $8.78B | $-465.00M | $-2.26B | $6.06B | (m) | (m) |
| 2023-12-31 | (m) | $0.00 | $8.78B | $-266.00M | $-2.29B | $6.22B | 12 month · $39.00M | (m) |
| 2023-09-30 | (m) | $0.00 | $8.76B | $-482.00M | $-2.15B | $6.13B | 3 month · $11.00M | 3 month · $35.00M 9 month · $94.00M |
| 2023-06-30 | (m) | $0.00 | $8.75B | $-281.00M | $-1.05B | $7.42B | 3 month · $8.00M | 3 month · $29.00M 6 month · $59.00M |
| 2023-03-31 | $0.00 | $0.00 | $8.74B | $-310.00M | $-954.00M | $7.48B | 3 month · $6.00M | 3 month · $-4.00M |
| 2022-12-31 | $0.00 | $0.00 | $8.74B | $-392.00M | $-1.06B | $7.29B | 12 month · $42.00M | 12 month · $-15.00M |
| 2022-09-30 | $0.00 | $0.00 | $8.72B | $-1.01B | $-972.00M | $6.71B | 3 month · $12.00M | 3 month · $11.00M 9 month · $-10.00M |
| 2022-06-30 | $0.00 | $0.00 | $8.71B | $-649.00M | $-923.00M | $7.12B | 3 month · $13.00M | 3 month · $1.00M 6 month · $-2.00M |
| 2022-03-31 | $0.00 | $0.00 | $8.70B | $-186.00M | $-901.00M | $7.58B | 3 month · $3.00M | 3 month · $-3.00M |
| 2021-12-31 | $0.00 | $0.00 | $8.70B | $-209.00M | $-979.00M | $7.51B | 12 month · $46.00M | 12 month · $-28.00M |
| 2021-09-30 | $0.00 | $0.00 | $8.68B | $-146.00M | $-852.00M | $7.68B | 3 month · $17.00M | 3 month · $-8.00M 9 month · $-22.00M |
| 2021-06-30 | $0.00 | $0.00 | $8.66B | $65.00M | $-748.00M | $7.98B | 3 month · $16.00M | 3 month · $-7.00M 6 month · $-14.00M |
| 2021-03-31 | $0.00 | $0.00 | $8.65B | $-102.00M | $-538.00M | $8.01B | 3 month · $15.00M | 3 month · $-7.00M |
| 2020-12-31 | $0.00 | $0.00 | $8.65B | $303.00M | $-477.00M | $8.46B | 12 month · $47.00M | 12 month · $-7.00M |
| 2020-09-30 | $0.00 | $0.00 | $8.62B | $-121.80M | $-154.40M | $8.34B | 3 month · $11.00M | (m) |
| 2020-06-30 | $0.00 | $0.00 | $6.89B | $-214.80M | $-19.40M | $6.65B | 3 month · $8.00M | (m) |
| 2020-03-31 | $0.00 | $0.00 | $6.87B | $-242.60M | $33.80M | $6.66B | 3 month · $11.00M | (m) |
| 2019-12-31 | $0.00 | $0.00 | $5.64B | $-173.70M | $84.30M | $5.54B | 12 month · $41.00M | (m) |
| 2019-09-30 | (m) | $0.00 | $5.65B | $-252.50M | $93.80M | $5.49B | 3 month · $11.30M | (m) |
| 2019-06-30 | (m) | $0.00 | $5.40B | $-214.80M | $83.80M | $5.27B | 3 month · $14.30M | (m) |
| 2019-03-31 | (m) | $0.00 | $5.40B | $-250.40M | $47.90M | $5.20B | 3 month · $2.40M | (m) |
| 2018-12-31 | $0.00 | $0.00 | $5.40B | $-222.20M | $16.40M | $5.20B | 12 month · $1.80M | (m) |
| 2018-09-30 | (m) | $0.00 | $5.35B | $-210.30M | (m) | $5.14B | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $7.58B | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | $7.90B | (m) | (m) |
| 2017-12-31 | (m) | $0.00 | $0.00 | $-256.60M | $0.00 | $7.78B | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | $7.96B | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | $7.02B | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | $7.43B | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |